

Supplementary Materials

Supplementary Table 1. Overview of general and surgery-specific data with respect to surgeon-defined nerve-sparing status (NS vs. NNS)

Variable	NS (n = 176)	NNS (n = 54)	P-value
Follow-up (mo)	48 (30–84)	45 (24–73.5)	0.40 ^{a)}
Age (yr)	63 (58–66)	65 (62–69)	0.0015 ^{a)}
Bilateral NS	143 (81)	-	-
Unilateral NS	33 (19)	-	-

Values are presented as median (interquartile range) or number (%).

NS, nerve-sparing; NNS, non-NS.

^{a)}Mann-Whitney U-test.

Supplementary Table 2. Overview of oncological data with respect to surgeon-defined nerve-sparing status (NS vs. NNS)

Variable	NS	NNS	P-value
Preoperative PSA (ng/mL)	5.44 (4.21–7)	6.85 (5.5–10.22)	0.0003 ^{a)}
Preoperative PSA density	0.17 (0.12–0.24)	0.19 (0.14–0.32)	0.023 ^{a)}
Prostate volume (mL)	33 (25–45)	34 (26–44)	0.90 ^{a)}
Maximum Gleason score (biopsy)	n = 175	n = 54	<0.0001 ^{a)}
6	96 (55)	10 (19)	
7	74 (42)	19 (35)	
8–9	5 (3)	25 (46)	
Clinical tumor stage	n = 176	n = 54	0.052 ^{a)}
cT1	132 (75)	33 (61)	
cT2	43 (24)	21 (39)	
cT3	1 (1)	0 (0)	
EAU risk group	n = 176	n = 54	<0.0001 ^{a)}
1	80 (46)	7 (13)	
2	84 (48)	20 (37)	
3	12 (7)	27 (50)	
Gleason score (RP)	n = 176	n = 54	<0.0001 ^{a)}
6	59 (34)	5 (9)	
7	102 (58)	24 (44)	
8–10	15 (9)	25 (46)	
Pathological tumor stage	n = 174	n = 54	<0.0001 ^{a)}
pT2	140 (80)	29 (54)	
pT3	34 (20)	24 (44)	
pT4	0	1 (2)	
Lymph node status	n = 176	n = 54	0.003 ^{b)}
pN0/X	171 (97)	46 (85)	
pN1	5 (3)	8 (15)	
Margins	n = 176	n = 54	0.026 ^{a)}
R0	128 (73)	32 (59)	
R1	42 (24)	14 (26)	
R2	6 (3)	8 (15)	
Metastasis	3/176 (2)	0/54 (0)	0.45 ^{b)}

Values are presented as median (interquartile range) or number (%).

NS, nerve-sparing; NNS, non-NS; PSA, prostate-specific antigen; EAU, European Association of Urology; RP, radical prostatectomy.

^{a)}Mann-Whitney U-test. ^{b)}Fisher exact test.